CA2815426A1 - Compositions and methods for the generation of platelets and methods of use thereof - Google Patents

Compositions and methods for the generation of platelets and methods of use thereof Download PDF

Info

Publication number
CA2815426A1
CA2815426A1 CA2815426A CA2815426A CA2815426A1 CA 2815426 A1 CA2815426 A1 CA 2815426A1 CA 2815426 A CA2815426 A CA 2815426A CA 2815426 A CA2815426 A CA 2815426A CA 2815426 A1 CA2815426 A1 CA 2815426A1
Authority
CA
Canada
Prior art keywords
cells
platelets
megakaryocytes
gata
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2815426A
Other languages
English (en)
French (fr)
Inventor
Mortimer Poncz
Mitchell Weiss
Paul Gadue
Deborah French
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of CA2815426A1 publication Critical patent/CA2815426A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2311—Interleukin-11 (IL-11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2815426A 2010-10-25 2011-10-25 Compositions and methods for the generation of platelets and methods of use thereof Abandoned CA2815426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40651410P 2010-10-25 2010-10-25
US61/406,514 2010-10-25
PCT/US2011/057716 WO2012061146A1 (en) 2010-10-25 2011-10-25 Compositions and methods for the generation of platelets and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2815426A1 true CA2815426A1 (en) 2012-05-10

Family

ID=46024776

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2815426A Abandoned CA2815426A1 (en) 2010-10-25 2011-10-25 Compositions and methods for the generation of platelets and methods of use thereof

Country Status (6)

Country Link
US (1) US9259443B2 (https=)
EP (1) EP2633047A4 (https=)
JP (1) JP6126004B2 (https=)
AU (1) AU2011323729B2 (https=)
CA (1) CA2815426A1 (https=)
WO (1) WO2012061146A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
EP3322800A4 (en) * 2015-07-13 2019-05-01 University of Utah Research Foundation PROCESS FOR THE PRODUCTION OF RED BLOOD BODIES AND BLOOD PLATES IN VITRO AND USES THEREOF
WO2018053288A1 (en) * 2016-09-16 2018-03-22 The Children's Hospital Of Philadelphia Methods and compositions for identification and enrichment of platelet-producing megakaryocytes (mks)
JP2021509812A (ja) 2018-01-05 2021-04-08 プレートレット バイオジェネシス， インコーポレイテッド 巨核球を産生するための組成物および方法
AU2019291955A1 (en) 2018-06-29 2021-02-18 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
JP2022512622A (ja) * 2018-10-05 2022-02-07 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 改変受容体を含む血小板の作製方法及びその使用法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824297A (en) 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5817662A (en) 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
DE69635899T2 (de) 1995-11-17 2006-11-23 Asahi Kasei Kabushiki Kaisha Polypeptid, das die differenzierung unterdrueckt
US5811297A (en) 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
DE69736109T2 (de) 1996-07-16 2007-01-04 Asahi Kasei Kabushiki Kaisha Differenzierungsinhibitor
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
JPH11180877A (ja) * 1997-12-17 1999-07-06 Asahi Chem Ind Co Ltd 巨核球前駆細胞を含む細胞製剤及びその製造方法
WO1999055864A1 (fr) 1998-04-28 1999-11-04 Ono Pharmaceutical Co., Ltd. Nouveau polypeptide, adnc le codant et son utilisation
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6569662B1 (en) 2000-01-21 2003-05-27 Hyseq, Inc. Nucleic acids and polypeptides
US6586390B1 (en) 2000-01-21 2003-07-01 Hyseq, Inc. Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides
US6465620B1 (en) 2000-01-21 2002-10-15 Hyseq, Inc. Methods and materials relating to novel von Willebrand/Thrombospondin-like polypeptides and polynucleotides
US6673904B2 (en) 2000-12-23 2004-01-06 Kirin Beer Kabushiki Kaisha Stem cell growth factor-like polypeptides
CA2450125A1 (en) 2001-06-15 2002-12-27 Andre C. Schuh Gene therapy for hemophilia a
WO2003013570A1 (en) 2001-08-09 2003-02-20 Cornell Research Foundation, Inc. Platelet-derived growth factor protection of cardiac myocardium
EP1336846A1 (en) 2002-02-13 2003-08-20 Procorde GmbH Method for generating recombinant human platelets for identifying therapeutic target proteins
KR20050000400A (ko) 2002-04-12 2005-01-03 셀진 코포레이션 줄기 및 전구 세포 분화의 조절, 측정 및 이들의 용도
CA2488013A1 (en) 2002-05-30 2003-12-11 Celgene Corporation Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
US7012005B2 (en) 2002-06-25 2006-03-14 Siliconix Incorporated Self-aligned differential oxidation in trenches by ion implantation
EP1743024B1 (en) 2004-04-23 2011-09-28 Héma-Québec Method of expanding cord blood cells
CN105168250B (zh) 2004-10-25 2019-02-05 塞勒兰特治疗公司 增殖骨髓细胞群体的方法及其应用
US20070077654A1 (en) 2004-11-01 2007-04-05 Thomson James A Platelets from stem cells
JP2008518603A (ja) 2004-11-01 2008-06-05 ウイスコンシン アラムニ リサーチ ファンデーション 幹細胞由来の血小板
JPWO2007049749A1 (ja) * 2005-10-28 2009-04-30 ディナベック株式会社 血液凝固異常の治療方法
WO2008137533A1 (en) * 2007-05-04 2008-11-13 Reddy Us Therapeutics, Inc. Methods and compositions for upregulation of gata activity
WO2008151386A1 (en) 2007-06-15 2008-12-18 Australian Stem Cell Centre Ltd Megakaryocyte differentiation
US10047346B2 (en) 2008-08-08 2018-08-14 Mayo Foundation For Medical Education And Research Method of treating heart tissue using induced pluripotent stem cells
EP2499239A1 (en) 2009-11-11 2012-09-19 Sanford-Burnham Medical Research Institute METHOD FOR GENERATION AND REGULATION OF iPS CELLS AND COMPOSITIONS THEREOF

Also Published As

Publication number Publication date
US9259443B2 (en) 2016-02-16
AU2011323729B2 (en) 2016-08-04
JP6126004B2 (ja) 2017-05-10
WO2012061146A1 (en) 2012-05-10
EP2633047A4 (en) 2014-04-02
EP2633047A1 (en) 2013-09-04
US20140086883A1 (en) 2014-03-27
AU2011323729A1 (en) 2013-05-30
JP2014511118A (ja) 2014-05-08

Similar Documents

Publication Publication Date Title
US9259443B2 (en) Compositions and methods for the generation of platelets and methods of use thereof
JP4672370B2 (ja) 虚血の細胞ベースの治療
CN105385659B (zh) 分化细胞的新型制备方法
US20080057043A1 (en) Monocyte cell
KR102510368B1 (ko) 혈관 콜로니 형성 세포
US11001806B2 (en) Mammalian alveolar macrophages derived from pluripotent cells
JP2019165732A5 (https=)
CA2457694A1 (en) Platelet-derived growth factor protection of cardiac myocardium
GB2455472A (en) Structure enclosing hematopoietic progenitor cells from ES cells and method for preparing blood cells using the same
CN107532145A (zh) 含有巨核细胞的培养物的制造方法及使用该培养物的血小板的制造方法
JP7176766B2 (ja) Ｃｄ３１陽性ｃｄ４５陰性ｃｄ２００陽性の哺乳動物細胞からなる細胞集団、およびその利用
Figueiredo et al. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells
ES2536605A1 (es) Método de obtención de megacariocitos y plaquetas
CA3134782A1 (en) Method of generating hemangioblasts
US12146161B2 (en) Mammalian alveolar macrophages derived from pluripotent cells
JP2017514523A (ja) 細胞培養方法
CN103993028A (zh) 非病毒载体与cxcr4质粒的复合物及其制备方法和应用
US20250195581A1 (en) Cell preparation
Sim Understanding megakaryopoiesis and thrombopoiesis using human stem cells models
WO2023176709A1 (ja) 造血幹細胞移植における移植前処理を受けた患者を処置する方法および当該方法に用いるための組成物
CN110393801A (zh) 靶向促黄体生成素促进机体造血的应用
Brown Tutorial: Geometrical Optics and Ray Tracing

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161019

FZDE Discontinued

Effective date: 20191025